A Senate hearing on drug pricing on Thursday featured testimony from Novo Nordisk about the cost of its diabetes drug, Ozempic. The hearing, led by Sen. Bernie Sanders, focused on the high prices of prescription drugs and the role of pharmaceutical companies in setting prices. Novo Nordisk defended its pricing strategy, stating that the cost of research and development is significant. Sanders criticized the company for increasing the price of Ozempic by more than 1,000% since its introduction.